BJA Advance Access published online on December 17, 2004
British Journal of Anaesthesia, doi:10.1093/bja/aei052
1 Department of Anaesthesiology, Aarhus University Hospital, Aarhus Sygehus, Denmark; Center for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Sygehus, Denmark
* To whom correspondence should be addressed. Background. Plasma substitutes such as hydroxyethyl starch (HES) and various dextrans may compromise the haemostatic system, thereby causing potentially dangerous bleeding. Whilst several mechanisms have been advanced to explain the nature of the coagulopathy induced by this colloid, there has been comparably little interest in devising ways to optimize haemostasis after a relative colloid overdose. Methods. Real-time whole blood (WB) clot formation profiles were recorded using a thrombelastographic method employing activation with tissue factor. The coagulation tracings were transformed into dynamic velocity profiles of WB clot formation. WB from healthy individuals (n=20) was exposed to haemodilution of Results. WB coagulation profiles changed significantly with decreased clot strength, and a compromised propagation phase of clot formation. The duration of the initiation phase of WB coagulation was unchanged. No statistical differences were detected amongst the HES solutions and dextran 70. However, dextran 70 returned a more suppressed clot development and strength compared with the HES solutions. Ex vivo haemostatic addition of washed platelets (75 x 109 litre-1) and factor VIII (0.6 IU ml-1) produced insignificant changes in clot initiation, propagation, and in the clot strength. In contrast, ex vivo addition of a fibrinogen concentrate (1 g litre-1) improved the coagulopathy induced by all of the three individual plasma expanders tested. Conclusion. Coagulopathy induced by haemodilution with either HES 200/0.5, HES 130/0.4, and dextran 70 may be improved by fibrinogen supplementation.
Accepted October 12, 2004
Laboratory Investigation
Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate
2 Department of Anaesthesiology, Aarhus University Hospital, Aarhus Sygehus, Denmark
3 Center for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby Sygehus, Denmark
J. Ingerslev, E-mail: ingerslev{at}ki.au.dk
Abstract 
55% with isotonic saline, HES 200/0.5, HES 130/0.4, and dextran 70, respectively. Possible modalities for improvement of the induced coagulopathy were explored, in particular ex vivo addition of a fibrinogen concentrate.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Bolliger, F. Szlam, R. J. Molinaro, N. Rahe-Meyer, J. H. Levy, and K. A. Tanaka Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model Br. J. Anaesth., June 1, 2009; 102(6): 793 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moor, T. Woolley, M. Midwinter, C. Fenger-Eriksen, J. Ingerslev, and B. Sorensen Coagulation tests in future studies: what to use? Br. J. Anaesth., May 1, 2009; 102(5): 716 - 717. [Full Text] [PDF]
|
|
|
|
|
|
C. Fenger-Eriksen, M. Lindberg-Larsen, A. Q. Christensen, J. Ingerslev, and B. Sorensen Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations Br. J. Anaesth., December 1, 2008; 101(6): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Haas, D. Fries, C. Velik-Salchner, C. Reif, A. Klingler, and P. Innerhofer The In Vitro Effects of Fibrinogen Concentrate, Factor XIII and Fresh Frozen Plasma on Impaired Clot Formation After 60% Dilution Anesth. Analg., May 1, 2008; 106(5): 1360 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. McDonald and K. Ryland Coagulopathy in trauma: optimising haematological status Trauma, April 1, 2008; 10(2): 109 - 123. [Abstract] [PDF]
|
|
|
|
|
|
V. G. Nielsen and J. H. Levy Fibrinogen and Bleeding: Old Molecule New Ideas Anesth. Analg., October 1, 2007; 105(4): 902 - 903. [Full Text] [PDF]
|
|
|
|
|
|
M. Mittermayr, W. Streif, T. Haas, D. Fries, C. Velik-Salchner, A. Klingler, E. Oswald, C. Bach, M. Schnapka-Koepf, and P. Innerhofer Hemostatic Changes After Crystalloid or Colloid Fluid Administration During Major Orthopedic Surgery: The Role of Fibrinogen Administration Anesth. Analg., October 1, 2007; 105(4): 905 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fries, T. Haas, A. Klingler, W. Streif, G. Klima, J. Martini, H. Wagner-Berger, and P. Innerhofer Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model Br. J. Anaesth., October 1, 2006; 97(4): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Niemi, R. T. Suojaranta-Ylinen, S. I. Kukkonen, and A. H. Kuitunen Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth. Analg., April 1, 2006; 102(4): 998 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. De Lorenzo, A. Calatzis, U. Welsch, and B. Heindl Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth. Analg., April 1, 2006; 102(4): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fries, P. Innerhofer, C. Reif, W. Streif, A. Klingler, W. Schobersberger, C. Velik-Salchner, and B. Friesenecker The Effect of Fibrinogen Substitution on Reversal of Dilutional Coagulopathy: An In Vitro Model Anesth. Analg., February 1, 2006; 102(2): 347 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sorensen, C. Fenger-Eriksen, and J. Ingerslev Recombinant factor VIIa fails to correct coagulopathy induced by haemodilution with colloid Br. J. Anaesth., June 1, 2005; 94(6): 862 - 863. [Full Text] [PDF]
|
|